About Evgen Pharma PLC
Evgen Pharma PLC is a United Kingdom-based clinical-stage drug development company. The Company's lead programs are focused on the treatment of cancers, such as breast and prostate cancer, and neurological conditions, such as subarachnoid hemorrhage. The Company has completed Phase I trials for its development product, SFX-01. It is carrying out preclinical work in relapsing remitting multiple sclerosis. It is also conducting preclinical work for two sulforaphane analogues, SFX-02 and SFX-03 for nuclear respiratory factor (Nrf) 2 activation, anti-cancer activity and genotoxicity. The Company's core technology is Sulforadex, a synthetic and stabilized version of a plant derived compound, sulforaphane, which is an anti-cancer agent. Sulforadex is a complex of sulforaphane and alpha-cyclodextrin in a stable powder, which is in a group of compounds known as antioxidant inflammation modulators (AIMs), affects the activity of transcription factors and thereby influencing gene expression.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: EVG
- CUSIP:
Key Metrics:
- Previous Close: $0.34
- 50 Day Moving Average: $27.25
- 200 Day Moving Average: $20.90
- 52-Week Range: GBX 14.50 - GBX 45
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $17.63M
- Outstanding Shares: 73,142,000
Additional Links:
Earnings History for Evgen Pharma PLC (LON:EVG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Evgen Pharma PLC (LON:EVG)Current Year EPS Consensus Estimate: $4.90 EPS
Dividend History for Evgen Pharma PLC (LON:EVG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Evgen Pharma PLC (LON:EVG)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/18/2016 | Clare,Barry | Insider | Buy | 40,000 | GBX 22 | £8,800 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Evgen Pharma PLC (LON:EVG)
